MoneyWorks4Me

The sales for the September 2023 quarter moved up 25.14% to Rs. 965.76 millions as compared to Rs. 771.77 millions during the corresponding quarter last year.A comparatively good net profit growth of 34.97% to Rs. 183.78 millions was reported for the quarter ended September 2023 compared to Rs. 136.16 millions of previous same quarter.OP of the company witnessed a marginal growth to 274.03 millions from 209.46 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 965.76 771.77 25.14 1819.25 1492.87 21.86 3115.29 2727.98 14.20
Other Income 7.85 20.00 -60.75 520.34 32.45 1503.51 98.08 90.80 8.02
PBIDT 274.03 209.46 30.83 1034.29 336.59 207.28 846.96 817.28 3.63
Interest 0.33 0.26 26.92 0.68 0.54 25.93 1.35 0.95 42.11
PBDT 273.70 209.20 30.83 1033.61 336.05 207.58 845.61 816.33 3.59
Depreciation 26.09 25.07 4.07 51.16 49.16 4.07 102.83 95.61 7.55
PBT 247.61 184.13 34.48 982.45 286.89 242.45 742.78 720.72 3.06
TAX 63.83 47.97 33.06 123.80 72.95 69.71 187.51 175.61 6.78
Deferred Tax -2.32 0.77 -401.30 -3.00 -0.31 867.74 4.97 -4.56 -208.99
PAT 183.78 136.16 34.97 858.65 213.94 301.35 555.27 545.11 1.86
Equity 223.65 223.64 0.00 223.65 223.64 0.00 223.65 223.60 0.02
PBIDTM(%) 28.37 27.14 4.55 56.85 22.55 152.16 27.19 29.96 -9.25
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..